Abeona Therapeutics (NASDAQ:ABEO) CFO Sells $47,425.56 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Joseph Vazzano sold 9,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total transaction of $47,425.56. Following the transaction, the chief financial officer owned 482,888 shares in the company, valued at $2,491,702.08. The trade was a 1.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joseph Walter Vazzano also recently made the following trade(s):

• On Tuesday, July 21st, Joseph Vazzano sold 1,478 shares of Abeona Therapeutics stock. The stock was sold at an average price of $6.53, for a total transaction of $9,651.34.
• On Thursday, July 9th, Joseph Vazzano sold 24,880 shares of Abeona Therapeutics stock. The shares were sold at an average price of $6.96, for a total transaction of $173,164.80.

Abeona Therapeutics Stock Performance

Shares of NASDAQ ABEO traded down $0.13 during mid-day trading on Tuesday, hitting $5.16. The stock had a trading volume of 1,253,359 shares, compared to its average volume of 1,359,931. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.40 and a current ratio of 6.63. The company has a 50 day moving average of $6.07 and a two-hundred day moving average of $5.72. Abeona Therapeutics Inc. has a twelve month low of $4.00 and a twelve month high of $7.65. The firm has a market cap of $295.07 million, a PE ratio of -4.73 and a beta of 1.33.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The business had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million. Research analysts predict that Abeona Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on ABEO shares. Weiss Ratings downgraded Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 17th. UBS Group reissued a “buy” rating on shares of Abeona Therapeutics in a research report on Friday. Wall Street Zen raised shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. HC Wainwright reiterated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday. Finally, Oppenheimer reissued an “outperform” rating and set a $21.00 target price (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds have recently modified their holdings of ABEO. Royal Bank of Canada increased its stake in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 2,155 shares in the last quarter. Riverwater Partners LLC grew its holdings in Abeona Therapeutics by 22.2% in the fourth quarter. Riverwater Partners LLC now owns 19,375 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 3,518 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Abeona Therapeutics in the first quarter valued at approximately $154,000. AXQ Capital LP purchased a new stake in shares of Abeona Therapeutics in the fourth quarter valued at approximately $177,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $256,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for patients with serious and life-threatening genetic diseases. The company’s programs are designed to address conditions for which existing treatment options are limited or inadequate.

Abeona’s lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and chronic wounds.